查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1714641

疫苗市场按类型、疫苗组合、供应来源、疫苗分类、给药途径、适应症、年龄层、最终用户划分 - 2025-2030 年全球预测

Vaccines Market by Type, Vaccine Combination, Source, Vaccine Classification, Route of Administration, Indication, Age Group, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计疫苗市场规模在 2024 年将达到 837.9 亿美元，到 2025 年将以 7.72% 的复合年增长率增长至 901.9 亿美元，到 2030 年将达到 1309.4 亿美元。

主要市场统计数据
基准年2024年 837.9亿美元
预计年份：2025年 901.9亿美元
预测年份 2030 1309.4亿美元
复合年增长率（%） 7.72%

过去十年，疫苗产业经历了前所未有的成长和转型。技术进步、对全球卫生安全的日益增长的担忧以及对新兴疾病快速反应的需求不断增加共同再形成了市场。当今的疫苗格局不仅由突破性的科学创新决定，还由不断变化的患者需求和动态的监管格局决定。研究人员和行业专家正在以一种上一代人无法想像的方式进行合作，共用见解和最佳实践，以应对复杂的健康挑战。

这份全面的执行摘要探讨并概述了将继续重新定义疫苗研究和製造的关键趋势、市场驱动因素和颠覆性创新。我们检验改进的製造流程、新的交付平台和整合的数位技术如何加速疫苗开发的步伐。当公共卫生议题成为全球政策讨论的焦点时，相关人员面临的挑战是如何保持敏捷和应对力。该报告提供了深入的分析，以帮助您做出策略决策并在竞争日益激烈的全球市场中最大限度地发挥您的潜力。

改变疫苗市场

在科学突破、投资增加和策略调整的推动下，疫苗产业正在经历转型变革。传讯RNA技术创新和快速适应性实验室测试等最新发展正在重新定义传统的疫苗开发方法。这一转变是由简化的监管流程推动的，该流程可确保安全，而不会延迟关键的核准。

公共和私营部门正在利用数位技术和数据分析的力量，使研究更有效率、更准确地预测需求。新兴趋势包括针对特定人口统计和疾病特征的个人化疫苗接种策略，以及采用先进的製造技术来提高生产能力。跨国合作和跨学科伙伴关係正在进一步加速这些创新，使疫苗领域比以往任何时候都更具回应能力。随着这些动态变化，行业领导者正在寻求透过增强科学严谨性、提高业务效率和坚定不移地致力于应对全球健康挑战来最大限度地利用商业机会。

深入了解动态市场动态的市场区隔

对疫苗市场的深入研究揭示了复杂的细分结构，为了解该行业的各个要素提供了宝贵的见解。依疫苗类型细分包括灭活疫苗、减毒疫苗、传讯RNA疫苗、次单元疫苗、重组疫苗、多醣体疫苗、结合疫苗、类毒素疫苗和病毒载体疫苗。同样重要的是按疫苗组合进行细分，区分单价疫苗和多效价疫苗。此外，在来源类别中区分人用疫苗和兽用疫苗可以进行更详细的分析。此外，市场分为预防性疫苗和治疗性疫苗，满足预防和治疗需求。

给药途径也是一个重要因素，可以包括肌肉注射、鼻腔内注射、口服和皮下给药，适应症分为感染疾病疾病和非感染疾病。感染疾病又细分为肝炎、人类乳突病毒、流感、麻疹、脑膜炎球菌疾病、百日咳、肺炎球菌疾病、狂犬病、轮状病毒、破伤风、水痘等，其中特别值得注意。同时，在非传染性疾病领域，自体免疫疾病和癌症疫苗等领域正受到关注。这些都透过区分成人、老年人和儿童（后者进一步分为婴儿）的人口统计见解以及涵盖学术和研究机构、医院诊所、疫苗接种中心等的最终用户分类来补充。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 感染疾病的传播增加了对疫苗的需求
      • 各国政府支持疫苗接种计画的措施和措施正在不断扩大
      • 社交媒体和数位平台传播有关疫苗益处的认识和教育
    • 限制因素
      • 疫苗研发和经销成本高昂
    • 机会
      • 疫苗生产和分发的技术进步
      • 增加先进疫苗製剂研发活动的投资
    • 任务
      • 因应疫苗核准复杂而漫长的监管环境
  • 市场区隔分析
    • 类型：传讯RNA疫苗非常有效，因此非常重要
    • 最终用户：医院和诊所的疫苗采用率有所提高，以应对紧急公共卫生事件
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章疫苗市场（按类型）

  • 介绍
  • 灭活疫苗
  • 减毒活疫苗
  • 传讯RNA疫苗
  • 次单元、重组疫苗、多醣体疫苗和结合疫苗
  • 类毒素疫苗
  • 病毒载体疫苗

第七章疫苗市场（依疫苗分类）

  • 介绍
  • 单价疫苗
  • 多效价疫苗

8. 疫苗市场（依供应来源）

  • 介绍
  • 人类疫苗
  • 兽用疫苗

9. 疫苗市场（依疫苗类别）

  • 介绍
  • 预防性疫苗
  • 治疗性疫苗

第十章 疫苗市场（依接种途径）

  • 介绍
  • 肌肉注射
  • 鼻内
  • 口服
  • 皮下

第11章疫苗市场（按适应症）

  • 介绍
  • 感染疾病
    • 肝炎
    • 人类乳突病毒
    • 流感
    • 麻疹
    • 病菌感染
    • 百日咳
    • 肺炎链球菌感染
    • 狂犬病
    • 轮状病毒
    • 破伤风
    • 水痘
  • 非传染性疾病
    • 自体免疫疾病
    • 癌症疫苗

第十二章 疫苗市场（依年龄层）

  • 介绍
  • 成人
  • 老年人
  • 孩子们
    • 婴儿
    • 婴儿

第十三章疫苗市场（依最终用户）

  • 介绍
  • 学术研究所
  • 医院和诊所
  • 疫苗接种中心

14.美洲疫苗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

15. 亚太疫苗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

16.欧洲、中东和非洲疫苗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat BIoTech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake BIoTechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac NV
  • Daiichi Sankyo Company, Limited.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac BIoTech Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA0513E

The Vaccines Market was valued at USD 83.79 billion in 2024 and is projected to grow to USD 90.19 billion in 2025, with a CAGR of 7.72%, reaching USD 130.94 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 83.79 billion
Estimated Year [2025] USD 90.19 billion
Forecast Year [2030] USD 130.94 billion
CAGR (%) 7.72%

The vaccine industry has witnessed unparalleled growth and transformation over the past decade. Advances in technology, a heightened focus on global health security, and an increased demand for rapid responses to emerging diseases have collectively reshaped the market. Today's vaccine landscape is not only defined by breakthrough scientific innovations but also by evolving patient needs and dynamic regulatory environments. Researchers and industry experts are working together in ways that were unthinkable a generation ago, sharing insights and best practices to combat complex health challenges.

This comprehensive executive summary sets the stage by exploring key trends, market drivers, and disruptive innovations that continue to redefine vaccine research and production. It examines how improved manufacturing processes, novel delivery platforms, and integrated digital technologies have accelerated the pace of vaccine development. In an age where public health concerns are at the forefront of global policy discussions, stakeholders are challenged to remain agile and responsive. This report provides an in-depth analysis designed to inform strategic decision-making and maximize potential in an increasingly competitive global marketplace.

Transformative Shifts in the Vaccine Landscape

The vaccine sector is experiencing transformative shifts driven by scientific breakthroughs, increased investments, and strategic realignments. Recent developments, such as messenger RNA innovations and rapid adaptive clinical trials, have redefined traditional vaccine development practices. This shift is bolstered by streamlined regulatory processes that ensure safety without delaying critical approvals.

Public and private sectors are harnessing the power of digital technologies and data analytics to improve research efficiency and forecast demand accurately. Emerging trends include a focus on personalized immunization strategies that cater to specific demographics and disease profiles, as well as the adoption of advanced manufacturing techniques that bolster production capacities. Collaborative research across international borders and interdisciplinary partnerships has further amplified these innovations, making the vaccine landscape more responsive than ever. With these dynamic changes, industry leaders are set to capitalize on opportunities driven by enhanced scientific rigor, operational efficiencies, and an unwavering commitment to addressing global health challenges.

In-depth Segmentation Insights Driving Market Dynamics

A thorough examination of the vaccine market reveals a complex segmentation structure that provides valuable insights into the diverse elements of the industry. The segmentation based on type dissects the market into inactivated vaccines, live-attenuated vaccines, messenger RNA vaccines, as well as subunit, recombinant, polysaccharide, conjugate, toxoid, and viral vector vaccines. Equally critical is the segmentation based on vaccine combination, which distinguishes between mono-valent and multi-valent vaccines. A further layer of analysis is provided by distinguishing between human and veterinary vaccines under the source category. Moreover, the market is methodically classified into preventive vaccines and therapeutic vaccines, addressing both prophylactic and treatment-oriented needs.

The route of administration is another key factor, covering intramuscular, intranasal, oral, and subcutaneous methods, while the indication-based segmentation divides the market into infectious diseases and non-infectious diseases. Infectious diseases merit special attention, as they are further subdivided into conditions such as hepatitis, human papillomavirus, influenza, measles, meningococcal disease, pertussis, pneumococcal disease, rabies, rotavirus, tetanus, and varicella. Meanwhile, non-infectious diseases highlight segments like autoimmune diseases and cancer vaccines. Complementing these are demographic insights that differentiate between adult, geriatric, and pediatric populations-the latter further broken down into infants and toddlers-and end user classifications that encompass academic and research institutes, hospitals and clinics, as well as vaccination centers.

Based on Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.

Based on Vaccine Combination, market is studied across Mono-Valent Vaccines and Multi-Valent Vaccines.

Based on Source, market is studied across Human Vaccines and Veterinary Vaccines.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Route of Administration, market is studied across Intramuscular, Intranasal, Oral, and Subcutaneous.

Based on Indication, market is studied across Infectious Diseases and Non-Infectious Diseases. The Infectious Diseases is further studied across Hepatitis, Human Papillomavirus, Influenza, Measles, Meningococcal Disease, Pertussis, Pneumococcal Disease, Rabies, Rotavirus, Tetanus, and Varicella. The Non-Infectious Diseases is further studied across Autoimmune Diseases and Cancer Vaccines.

Based on Age Group, market is studied across Adult, Geriatric, and Pediatric. The Pediatric is further studied across Infants and Toddlers.

Based on End User, market is studied across Academic & Research Institutes, Hospitals & Clinics, and Vaccination Centers.

Regional Market Perspectives and Emerging Trends

The global vaccine market exhibits distinct variations across regions, each characterized by unique challenges and opportunities that contribute to a dynamic industry landscape. In the Americas, the market benefits from a mature infrastructure supported by advanced research facilities and a history of successful immunization programs. By contrast, in regions spanning Europe, the Middle East, and Africa, a blend of established healthcare systems and rapidly emerging markets fosters both continuity in research and innovation in deployment strategies.

The Asia-Pacific region stands out as a burgeoning powerhouse, where strong governmental support, increasing investments in healthcare infrastructure, and accelerating public-private partnerships are driving exponential growth. These regional variations compel stakeholders to tailor their strategies to local market conditions while remaining informed of global trends. Assessing regional insights ensures that emerging opportunities are comprehensively addressed, whether by leveraging the technological prowess of the Americas, the progressive reforms in Europe, the Middle East, and Africa, or the dynamic expansion seen in the Asia-Pacific region.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Players Shaping the Future of Vaccines

The competitive landscape in the vaccine market is defined by a host of influential companies that drive innovation and market growth on a global scale. Industry leaders such as Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, and Bavarian Nordic A/S have long been recognized for setting high standards in safety and efficacy. Equally significant are Bharat Biotech Ltd. and Biological E. Limited, whose cost-effective and scalable vaccine solutions have opened new avenues in emerging markets. Advanced biotech firms like BioNTech SE and Blue Lake Biotechnology are at the forefront of developing cutting-edge messenger RNA platforms, while Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, and CureVac N.V. are rapidly gaining ground in research and development.

The landscape is further enhanced by the contributions of Daiichi Sankyo Company, Limited., Gennova Biopharmaceuticals Limited, and GlaxoSmithKline PLC, alongside renowned institutions such as Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., and Merck & Co., Inc. Innovative companies like Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd. also play pivotal roles, complemented by Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited. Collectively, these organizations harness sophisticated technologies, cutting-edge research, and expansive distribution networks to drive market evolution and deliver impactful health solutions worldwide.

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders operating in the vaccine sector are encouraged to adopt a proactive approach that balances innovation with operational excellence. To stay competitive, it is essential to invest in modern research and development infrastructure and establish cross-functional partnerships that can accelerate the translation of scientific discovery into market-ready solutions. Embracing digital transformation-by integrating advanced data analytics and real-time monitoring systems-will enhance decision-making processes and facilitate refined market insights.

Furthermore, leaders should prioritize regulatory agility by actively engaging with policy makers to streamline approval mechanisms without compromising stringent safety standards. Strengthening supply chain processes and diversifying manufacturing capabilities will hedge against unforeseen disruptions while ensuring consistent product availability. Collaborative efforts with academic institutions, hospitals, and vaccination centers can further solidify market presence and expand outreach. By cultivating a culture of continuous improvement, transparent communication, and robust risk management, industry stakeholders can not only mitigate emerging challenges but also harness new opportunities in an evolving global landscape.

Conclusive Reflections on the Vaccine Industry

The vaccine market is at a pivotal juncture, marked by rapid scientific advancements and ever-evolving market demands. This executive summary has illustrated how the nuanced segmentation across vaccine type, combination, source, classification, route of administration, and indication provides a detailed framework for understanding market dynamics. In addition, demographic factors and end user insights enrich the overall analysis, offering a multi-dimensional view of the challenges and opportunities that lie ahead.

Regional insights reveal that mature markets, emerging economies, and dynamic growth regions each offer unique prospects that must be strategically leveraged. The sustained innovation and agility demonstrated by key industry players underlie a resilient ecosystem that is capable of responding to both current and future public health needs. Ultimately, the synthesis of these insights reinforces the importance of informed decision-making and strategic investments, empowering stakeholders to navigate an increasingly competitive and complex landscape with confidence and precision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of infectious diseases raising the need for vaccines
      • 5.1.1.2. Growing government initiatives and policies supporting vaccination programs around the world
      • 5.1.1.3. Social media and digital platforms amplifying awareness and education about the benefits of vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. High development and distribution costs associated with vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in vaccine production and distribution
      • 5.1.3.2. Rising investments in research and development activities for advanced vaccine formulation
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the complex and time-consuming regulatory landscape for vaccine approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Critical need for messenger RNA vaccines due to their high effectiveness
    • 5.2.2. End user: Rising adoption of vaccines across hospitals & clinics for emergency public health responses.
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
  • 6.3. Live-Attenuated Vaccines
  • 6.4. Messenger RNA Vaccines
  • 6.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 6.6. Toxoid Vaccines
  • 6.7. Viral Vector Vaccines

7. Vaccines Market, by Vaccine Combination

  • 7.1. Introduction
  • 7.2. Mono-Valent Vaccines
  • 7.3. Multi-Valent Vaccines

8. Vaccines Market, by Source

  • 8.1. Introduction
  • 8.2. Human Vaccines
  • 8.3. Veterinary Vaccines

9. Vaccines Market, by Vaccine Classification

  • 9.1. Introduction
  • 9.2. Preventive Vaccines
  • 9.3. Therapeutic Vaccines

10. Vaccines Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Vaccines Market, by Indication

  • 11.1. Introduction
  • 11.2. Infectious Diseases
    • 11.2.1. Hepatitis
    • 11.2.2. Human Papillomavirus
    • 11.2.3. Influenza
    • 11.2.4. Measles
    • 11.2.5. Meningococcal Disease
    • 11.2.6. Pertussis
    • 11.2.7. Pneumococcal Disease
    • 11.2.8. Rabies
    • 11.2.9. Rotavirus
    • 11.2.10. Tetanus
    • 11.2.11. Varicella
  • 11.3. Non-Infectious Diseases
    • 11.3.1. Autoimmune Diseases
    • 11.3.2. Cancer Vaccines

12. Vaccines Market, by Age Group

  • 12.1. Introduction
  • 12.2. Adult
  • 12.3. Geriatric
  • 12.4. Pediatric
    • 12.4.1. Infants
    • 12.4.2. Toddlers

13. Vaccines Market, by End User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
  • 13.3. Hospitals & Clinics
  • 13.4. Vaccination Centers

14. Americas Vaccines Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Vaccines Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Vaccines Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Scenario Analysis
    • 17.3.1. Mankind Pharma acquires Bharat Serums and Vaccines (BSV) for strategic expansion in Women's Health and Fertility market
    • 17.3.2. Sanofi and Novavax partner to co-commercialize new COVID-19 vaccine and develop flu-COVID combo shot
    • 17.3.3. CureVac and MD Anderson team up to develop mRNA-based cancer vaccines, paving the way for advanced cancer treatments
    • 17.3.4. Bavarian Nordic launches mpox vaccine in the U.S., boosting preventive healthcare and market innovation
    • 17.3.5. Bharat Biotech and Bilthoven Biologicals unite to boost global polio eradication efforts with enhanced OPV production
    • 17.3.6. Takeda forms partnership to boost global access to dengue vaccine, targeting hard-hit regions
    • 17.3.7. AstraZeneca bolsters vaccine capabilities by acquiring biotechnology firm Icosavax
    • 17.3.8. Serum Institute of India Partners with CEPI to increase global vaccine accessibility during epidemics
    • 17.3.9. GSK partners with Zhifei to exclusively distribute shingles vaccine Shingrix in China, aiming to enhance public health and vaccine access
    • 17.3.10. Janssen and Sanofi join forces to develop vaccine program to address unmet medical needs
  • 17.4. Strategy Analysis & Recommendation
    • 17.4.1. AstraZeneca PLC
    • 17.4.2. Pfizer Inc.
    • 17.4.3. GlaxoSmithKline PLC
    • 17.4.4. Merck & Co., Inc.
    • 17.4.5. Sanofi S.A.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech Ltd.
  • 6. Biological E. Limited
  • 7. BioNTech SE
  • 8. Blue Lake Biotechnology
  • 9. Capricor Therapeutics, Inc.
  • 10. Chongqing Zhifei Biological Products Co., Ltd.
  • 11. CSL Limited
  • 12. CureVac N.V.
  • 13. Daiichi Sankyo Company, Limited.
  • 14. Gennova Biopharmaceuticals Limited
  • 15. GlaxoSmithKline PLC
  • 16. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 17. Incepta Pharmaceuticals Ltd.
  • 18. Inovio Pharmaceuticals, Inc.
  • 19. Johnson & Johnson Services, Inc.
  • 20. Merck & Co., Inc.
  • 21. Moderna, Inc.
  • 22. Novavax, Inc.
  • 23. Pfizer Inc.
  • 24. Sanofi S.A.
  • 25. Serum Institute of India Pvt. Ltd.
  • 26. Sinovac Biotech Ltd.
  • 27. Takeda Pharmaceutical Company Limited
  • 28. VBI Vaccines Inc.
  • 29. Versatope Therapeutics
  • 30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. VACCINES MARKET MULTI-CURRENCY
  • FIGURE 2. VACCINES MARKET MULTI-LANGUAGE
  • FIGURE 3. VACCINES MARKET RESEARCH PROCESS
  • FIGURE 4. VACCINES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 23. GLOBAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 27. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 32. VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 33. VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY MONO-VALENT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY MULTI-VALENT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VACCINES MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. TAIWAN VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. THAILAND VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 265. VIETNAM VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 267. VIETNAM VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 288. DENMARK VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 289. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 290. DENMARK VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 291. DENMARK VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 299. EGYPT VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 300. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 301. EGYPT VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 302. EGYPT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 309. FINLAND VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 310. FINLAND VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 311. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 312. FINLAND VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 313. FINLAND VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 320. FRANCE VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 321. FRANCE VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 322. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 323. FRANCE VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 324. FRANCE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. GERMANY VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 332. GERMANY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 333. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 334. GERMANY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 335. GERMANY VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 336. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. ISRAEL VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 338. ISRAEL VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 339. ISRAEL VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 340. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 341. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 342. ISRAEL VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 343. ISRAEL VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 344. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 345. ISRAEL VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 346. ISRAEL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 347. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. ITALY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 349. ITALY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 350. ITALY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 351. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 352. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. ITALY VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 354. ITALY VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 355. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 356. ITALY VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 357. ITALY VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 358. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. NETHERLANDS VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 360. NETHERLANDS VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 361. NETHERLANDS VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 362. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 363. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 364. NETHERLANDS VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 365. NETHERLANDS VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 366. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 367. NETHERLANDS VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 368. NETHERLANDS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 369. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 370. NIGERIA VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 371. NIGERIA VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 372. NIGERIA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 373. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 374. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 375. NIGERIA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 376. NIGERIA VACCINES MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 377. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 378. NIGERIA VACCINES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
  • TABLE 379. NIGERIA VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 380. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 381. NORWAY VACCINES MARKET SIZE, BY VACCINE COMBINATION, 2018-2030 (USD MILLION)
  • TABLE 382. NORWAY VACCINES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 383. NORWAY VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 384. NORWAY VACCINES MAR